Day One Biopharmaceuticals (DAWN) Competitors $7.20 +0.22 (+3.15%) Closing price 04:00 PM EasternExtended Trading$7.14 -0.06 (-0.82%) As of 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DAWN vs. IMVT, GMTX, RXRX, CPRX, KNSA, OGN, ALVO, CNTA, IBRX, and TARSShould you be buying Day One Biopharmaceuticals stock or one of its competitors? The main competitors of Day One Biopharmaceuticals include Immunovant (IMVT), Gemini Therapeutics (GMTX), Recursion Pharmaceuticals (RXRX), Catalyst Pharmaceuticals (CPRX), Kiniksa Pharmaceuticals International (KNSA), Organon & Co. (OGN), Alvotech (ALVO), Centessa Pharmaceuticals (CNTA), ImmunityBio (IBRX), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "pharmaceutical products" industry. Day One Biopharmaceuticals vs. Its Competitors Immunovant Gemini Therapeutics Recursion Pharmaceuticals Catalyst Pharmaceuticals Kiniksa Pharmaceuticals International Organon & Co. Alvotech Centessa Pharmaceuticals ImmunityBio Tarsus Pharmaceuticals Day One Biopharmaceuticals (NASDAQ:DAWN) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings. Which has stronger valuation & earnings, DAWN or IMVT? Day One Biopharmaceuticals has higher revenue and earnings than Immunovant. Day One Biopharmaceuticals is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDay One Biopharmaceuticals$131.16M5.62-$95.50M-$0.95-7.58ImmunovantN/AN/A-$413.84M-$2.85-5.35 Which has more risk and volatility, DAWN or IMVT? Day One Biopharmaceuticals has a beta of -1.26, indicating that its stock price is 226% less volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Do insiders & institutionals hold more shares of DAWN or IMVT? 88.0% of Day One Biopharmaceuticals shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 6.2% of Day One Biopharmaceuticals shares are owned by insiders. Comparatively, 1.8% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media prefer DAWN or IMVT? In the previous week, Day One Biopharmaceuticals had 3 more articles in the media than Immunovant. MarketBeat recorded 12 mentions for Day One Biopharmaceuticals and 9 mentions for Immunovant. Immunovant's average media sentiment score of 0.87 beat Day One Biopharmaceuticals' score of 0.55 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Day One Biopharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is DAWN or IMVT more profitable? Immunovant has a net margin of 0.00% compared to Day One Biopharmaceuticals' net margin of -50.63%. Day One Biopharmaceuticals' return on equity of -19.01% beat Immunovant's return on equity.Company Net Margins Return on Equity Return on Assets Day One Biopharmaceuticals-50.63% -19.01% -16.99% Immunovant N/A -80.99%-72.23% Do analysts prefer DAWN or IMVT? Day One Biopharmaceuticals presently has a consensus target price of $25.29, suggesting a potential upside of 251.19%. Immunovant has a consensus target price of $35.20, suggesting a potential upside of 130.97%. Given Day One Biopharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Day One Biopharmaceuticals is more favorable than Immunovant.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Day One Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Immunovant 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.83 SummaryDay One Biopharmaceuticals beats Immunovant on 10 of the 15 factors compared between the two stocks. Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DAWN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DAWN vs. The Competition Export to ExcelMetricDay One BiopharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$737.50M$3.09B$5.82B$9.74BDividend YieldN/A2.23%3.84%4.09%P/E Ratio-7.5821.1431.1525.97Price / Sales5.62399.83475.57123.18Price / CashN/A43.0937.1558.38Price / Book1.608.079.116.39Net Income-$95.50M-$54.72M$3.26B$265.66M7 Day Performance6.67%2.62%2.11%1.98%1 Month Performance9.59%7.63%5.12%1.33%1 Year Performance-47.37%13.11%31.25%21.15% Day One Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DAWNDay One Biopharmaceuticals2.5233 of 5 stars$7.20+3.2%$25.29+251.2%-50.8%$737.50M$131.16M-7.5860News CoverageInsider TradeIMVTImmunovant3.0127 of 5 stars$15.26+0.3%$35.20+130.7%-54.3%$2.65BN/A-5.35120GMTXGemini TherapeuticsN/A$59.86-1.4%N/A+17.6%$2.59BN/A-59.8630RXRXRecursion Pharmaceuticals2.6387 of 5 stars$5.52-4.3%$7.00+26.8%-37.3%$2.51B$58.84M-3.10400Insider TradeCPRXCatalyst Pharmaceuticals4.9199 of 5 stars$20.23flat$33.20+64.1%+0.4%$2.48B$558.50M12.2680Positive NewsAnalyst DowngradeKNSAKiniksa Pharmaceuticals International2.5057 of 5 stars$33.72+1.0%$41.17+22.1%+27.1%$2.47B$423.24M843.21220Insider TradeOGNOrganon & Co.4.7554 of 5 stars$9.27-1.8%$18.00+94.2%-55.9%$2.45B$6.40B3.454,000Positive NewsALVOAlvotech2.4678 of 5 stars$9.00+12.2%$14.00+55.6%-31.7%$2.42B$491.98M39.131,032News CoverageShort Interest ↓Gap UpHigh Trading VolumeCNTACentessa Pharmaceuticals2.2017 of 5 stars$17.59-2.5%$28.10+59.7%+43.6%$2.42B$6.85M-9.83200IBRXImmunityBio2.5712 of 5 stars$2.43-4.7%$10.75+342.4%-49.1%$2.41B$14.74M-5.06590TARSTarsus Pharmaceuticals1.9611 of 5 stars$54.61+0.7%$66.67+22.1%+116.9%$2.29B$182.95M-23.4450News CoveragePositive News Related Companies and Tools Related Companies Immunovant Competitors Gemini Therapeutics Competitors Recursion Pharmaceuticals Competitors Catalyst Pharmaceuticals Competitors Kiniksa Pharmaceuticals International Competitors Organon & Co. Competitors Alvotech Competitors Centessa Pharmaceuticals Competitors ImmunityBio Competitors Tarsus Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DAWN) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access